Correction of endothelial dysfunction in patients with COPD and concomitant arterial hypertension

Abstract

Endothelial dysfunction is a common pathogenetic mechanism of COPD and hypertension. Identification of additional pleiotropic effects of antihypertensive drugs is very actual. Aims: To identify opportunities for correction of endothelial dysfunction in patients with COPD and concomitant hypertension with slow-release (SR) formulation of indapamide. Methods: 42 out-patients with COPD and concomitant hypertension were recruited (34 male, mean age of 66.5±8.4, %FEV1 58.4±11.5%, index smoker 44.6±20.1). COPD duration was 5.8±4.5 years, hypertension duration was 11.3±8.9 years. All patients were received indapamide SR 1.5 mg/day for 3 months. Endothelial dysfunction markers (endothelin-1, sP-selectin, ICAM-1) were assessed at baseline and after 3 month of treatment by enzyme-linked immunosorbent assay (ELISA). Results: Endothelin-1 level was higher in studied patients vs normal values at baseline (4.23 [0.69; 7.70] vs 0,26 fmol/ml) and significantly decreased average by 49.2% (p Conclusions: Endothelial dysfunction were observed in studied patients with COPD and concomitant hypertension. Indapamide SR treatment in complex therapy of COPD and concomitant hypertension leads to a significant reduction of endothelial dysfunction markers (endothelin-1, sP-selectin, ICAM-1), which indicates the presence of pleiotropic effects of indapamide.